Malling H J, Stahl Skov P
Laboratory of Clinical Allergology, Medical Department TTA, State University Hospital, Copenhagen, Denmark.
Allergy. 1988 Apr;43(3):228-38.
The interrelation of in vitro IgE-mediated parameters, i.e. serum-specific IgE (RAST), basophil cell-bound specific IgE, and histamine release from basophil leucocytes was investigated in a 1-year placebo-controlled, double-blind Cladosporium immunotherapy study involving 22 adult asthmatics. The intense and early burst (within 6 weeks of immunotherapy) of serum-specific IgE did not result in a corresponding increased binding of specific IgE molecules to basophils. Cell-bound IgE increased in the Cladosporium season in both groups at the same time as serum levels of specific IgE declined in the Cladosporium group. In the placebo group histamine release from circulating basophils paralleled changes in basophil-bound IgE. In Cladosporium-treated patients, histamine release cell sensitivity after a lag phase (during immunotherapy dose-increase) declined two log steps, i.e. the cells became less responding in spite of a significant increase in cell-bound IgE. To further evaluate the sensitizing capacity of circulating specific IgE, passive sensitization studies were performed using basophils from a single donor. Although sera taken at the maximal IgE-response showed an enhanced capacity of passive sensitization, the ratio between RAST and passive sensitization capacity increased significantly in Cladosporium-treated patients, implying a less than expected sensitization capacity of immunotherapy-induced specific IgE. The lack of active binding of IgE to basophils might be explained by a reduced Fc-affinity of immunotherapy-induced IgE in contrast to the Cladosporium-seasonally induced IgE. Regarding the decrease in histamine release in Cladosporium-treated patients in spite of an increased amount of cell-bound specific IgE, immunotherapy may initiate a decrease in mediator releasibility which is not caused by a reduction in the number of Fc-receptors but rather some yet unknown subcellular mechanisms regulating the histamine release. The described changes in IgE-mediated parameters do not seem to be caused by interference with either specific IgG1 or IgG4. Changes in histamine release in the Cladosporium season were the only IgE-mediated parameter significantly related to the graded clinical efficacy of immunotherapy.
在一项为期1年的安慰剂对照、双盲的枝孢菌免疫疗法研究中,对22名成年哮喘患者的体外IgE介导参数的相互关系进行了研究,这些参数包括血清特异性IgE(放射性变应原吸附试验)、嗜碱性粒细胞结合的特异性IgE以及嗜碱性白细胞的组胺释放。血清特异性IgE在免疫疗法的强烈且早期爆发(免疫疗法开始6周内)并未导致特异性IgE分子与嗜碱性粒细胞的结合相应增加。在枝孢菌季节,两组嗜碱性粒细胞结合的IgE均增加,与此同时,枝孢菌组血清特异性IgE水平下降。在安慰剂组中,循环嗜碱性粒细胞的组胺释放与嗜碱性粒细胞结合的IgE变化平行。在接受枝孢菌治疗的患者中,经过一个延迟期(免疫疗法剂量增加期间)后,组胺释放细胞敏感性下降了两个对数级,即尽管细胞结合的IgE显著增加,但细胞反应性降低。为了进一步评估循环特异性IgE的致敏能力,使用来自单一供体的嗜碱性粒细胞进行了被动致敏研究。尽管在最大IgE反应时采集的血清显示被动致敏能力增强,但在接受枝孢菌治疗的患者中,放射性变应原吸附试验与被动致敏能力的比值显著增加,这意味着免疫疗法诱导的特异性IgE的致敏能力低于预期。与枝孢菌季节性诱导的IgE相比,免疫疗法诱导的IgE与嗜碱性粒细胞缺乏活性结合可能是由于Fc亲和力降低所致。尽管细胞结合的特异性IgE量增加,但接受枝孢菌治疗的患者组胺释放减少,免疫疗法可能引发介质释放能力的下降,这不是由Fc受体数量减少引起的,而是由一些尚未明确的亚细胞机制调节组胺释放所致。所描述的IgE介导参数的变化似乎不是由对特异性IgG1或IgG4的干扰引起的。枝孢菌季节组胺释放的变化是唯一与免疫疗法分级临床疗效显著相关的IgE介导参数。